PDCD1 and head and neck squamous cell carcinoma: Our study demonstrated that the PCNA inhibitor AOH1996 suppressed HNSCC biological behaviors, impaired cancer stemness, prevented development and metastasis, enhanced the effect of anti-PD1 immunotherapy, promoted cellular DNA damage, and stimulated antitumor immune responses.